ACRO Biomedical, a company which has opened up its visibility in the international market and attracted international biomedical companies and investment teams to carry out cross-border cooperation, was awarded Innovation of the Year of the 2023 Taiwan BIO Awards with "The Application of ScCO2 Platform Technology in Regenerative Medicine Industry" at BIO-Asia Taiwan today.

Dr. Dar-Jen Hsieh, CEO of ACRO Biomedical, said that Taiwan's development in the field of biomedicine can speak for itself, and the annual BIO-Asia Taiwan attracts top biomedical companies from all over the world to participate. In addition to summarizing the development trend of the global biotechnology industry, awards are also presented to recognize outstanding biotechnology companies. ACRO Biomedical was awarded the "Innovation of the Year", one of the three Taiwan BIO Awards in 2023.

The bone graft and bone matrix products that ACRO Biomedical has successfully developed have attracted many companies to seek strategic cooperation due to their excellent clinical performances. A Swiss company that is an international leader in the distribution of medical materials, is also discussing the possibility of being the general agency in Vietnam.

ACRO Biomedical has also received the EU patent "Acellular organs, and methods of producing the same." In addition, the hair follicle regeneration technology has also obtained the invention patent in Taiwan, and is currently conducting human clinical trials in Tri-Service General Hospital, Show Chwan Memorial Hospital, and Kaohsiung Medical University. This technology has received good reviews from patients suffering from thinning hair in Hong Kong.

Regenerative medicine has indeed opened up a new door for the human kind, and ACRO Biomedical is the guide to this door, bringing new hope to this earth.

URL: ACRO Biomedical, the Leader of Regenerative Medicine